1. Scrip
  2. >>Drug Pricing

Industry Looks At IRA Drawbacks And Silver Linings

Drug Pricing Changes Were Top Of Mind At J.P. Morgan

 
• By Jessica Merrill

Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.

two couple are showing half full and half empty side of water glass with their fingers
Industry Looking For Upsides From The IRA

One of the biopharma industry’s biggest worries has been how the Inflation Reduction Act (IRA) will impact US drug pricing and consequently innovation over the long term. So it was expected to be a key topic for one of the industry’s biggest meetings, the J.P. Morgan Healthcare Conference. But while the lack of specifics kept discussion limited during the main stage presentations, executives interviewed by Scrip offered a range of expectations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

More from Scrip